 The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment with cytarabine ara-C. In addition, the correlation between hENT1 human equilibrative nucleoside transporter 1 and overall survival will be studied. 